Organizations like yours are familiar to us. We are chemists, engineers, molecular biologists, researchers, and scientists who combine our technical understanding with legal, regulatory, and compliance excellence to provide you with well-informed counsel – from your patent portfolio development, protection, and monetization strategies to market entry and exit strategies.
Whether you are an inventor, start-up, venture capitalist, investor, Fortune 50 or Fortune 500 company, or research institution we help people like you on all aspects of pharmaceuticals, biotechnology and medical devices. We understand that regulatory and compliance will dominate your thinking – and can help you meet your requirements on every issue from M&A to tax, HR and real estate.
We know that often in this industry, time is of the essence, and we are proud that we continually demonstrate that we can work at speed without compromising on efficiency. This is demonstrated by our looking at patents for potential vaccines and detection methods, as well as dealing with urgent approval for medical devices and personal protective equipment.
Whatever your background, we can help you commercialize your inventions, protect key intellectual property and structure your business and partnerships to best enable you to bring the next generation of medicines, products and services to market.
Our lawyers use their experience and knowledge of the life sciences and healthcare fields to work across many cases and sectors. Some of our recent work includes:
- a pan-European review of new product launch marketing materials for EU and country-by-country compliance
- prosecution of pharmaceutical and biotechnology patent applications through our large U.S. patent team. We also have patent attorney capability in Finland and South Africa
- patent litigation across the U.S. and Europe including Hatch-Waxman launch strategies
- assessment of mobile apps as medical devices and advice on classification
- antitrust litigation in relation to pricing and market access and to parallel importation, including refusal to supply issues
- regulatory litigation concerning data exclusivity
- advice on clinical trials agreements and regulation
- implementing an EU-wide privacy compliance program and preparing for the arrival of the new data privacy law
Key contacts
Latest Insights
- legal updatesQuadrupled Penalties – Germany to tighten scheme for corporate fines
- legal updatesWithdrawal of a company car during suspension on the basis of a blanket suspension clause gives rise to compensation
- legal updatesThe EDPB’s new scientific research guidelines: a welcome route map, but no shortcut for “research” by assertion
- legal updatesHong Kong: Open consultation on listing reforms
Latest News
- firm newsEversheds Sutherland Advises The Centurion Foundation on Completed Acquisition of Roger Williams Medical Center and Fatima Hospital
- client newsEversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
- client newsEversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
- client newsEversheds Sutherland advises Humanwell Healthcare Group on the Acquisition of the assets of Paion AG and Paion Deutschland GmbH including shares in Paion Holdings UK
legal updates
May 26, 2026
Quadrupled Penalties – Germany to tighten scheme for corporate fines
legal updates
May 12, 2026
Withdrawal of a company car during suspension on the basis of a blanket sus...
legal updates
April 28, 2026
The EDPB’s new scientific research guidelines: a welcome route map, but no ...
legal updates
April 14, 2026
Hong Kong: Open consultation on listing reforms
firm news
March 20, 2026
Eversheds Sutherland Advises The Centurion Foundation on Completed Acquisit...
client news
November 06, 2025
Eversheds Sutherland advises on £5.2bn disposal of Barchester Healthcare
client news
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of C...
client news
March 13, 2024
Eversheds Sutherland advises Humanwell Healthcare Group on the Acquisition ...